IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
UP-0280738
(2005-11-16)
|
등록번호 |
US-7575760
(2009-08-31)
|
우선권정보 |
DE-101 52 169(2001-10-23) |
발명자
/ 주소 |
- Gianesello, Valter
- Cappellini, Claudia
- Marocchi, Michael David
|
출원인 / 주소 |
- Boehringer Ingelheim International GmbH
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
1 인용 특허 :
4 |
초록
A tablet with enhanced compliance by humans, in particular children and/or juveniles, comprising: (a) a vitamin; (b) lysine or a pharmaceutically acceptable salt thereof; (c) a sweetener; and (d) a pharmaceutically or dietetically acceptable carrier.
대표청구항
▼
We claim: 1. A non-effervescing tablet consisting essentially of: (a) at least one vitamin; (b) at least one mineral selected from the group consisting of: manganese (II) gluconate, copper (II) carbonate, zinc oxide, and magnesium oxide, (c) 10-100 mg of lysine or a pharmaceutically acceptable salt
We claim: 1. A non-effervescing tablet consisting essentially of: (a) at least one vitamin; (b) at least one mineral selected from the group consisting of: manganese (II) gluconate, copper (II) carbonate, zinc oxide, and magnesium oxide, (c) 10-100 mg of lysine or a pharmaceutically acceptable salt thereof; (d) at least one sweetener; (e) a pharmaceutically or dietetically acceptable carrier; and (f) optionally a flavoring agent capable of masking the flavor of lysine, wherein said tablet is obtainable by mixing of the different components (a) to (e) and wherein said tablet is formed by direct compression. 2. The tablet according to claim 1, wherein the vitamin is selected from the group consisting of: β-carotene, vitamin A palmitate, vitamin B1 nitrate, vitamin B2, vitamin B6 hydrochloride, vitamin B12, vitamin C, vitamin D3, vitamin E acetate, folic acid, vitamin H, and vitamin PP. 3. The tablet according to claim 1, wherein the lysine or a pharmaceutically acceptable salt thereof is (L)-lysine monohydrochloride. 4. The tablet according to claim 1, wherein lysine or a pharmaceutically acceptable salt thereof consists essentially of 10 mg to 100 mg of (L)-lysine monohydrochloride. 5. The tablet according to claim 1, wherein the sweetener is selected from the group consisting of: calcium saccharinate, ammonium cyclamate, ammonium glycirhizinate, aspartame, glucose, and glucitols. 6. The tablet according to claim 1, wherein the flavoring agent is selected from the group consisting of: natural citrus and orange flavor. 7. The tablet according to claim 1, wherein a pharmaceutically or dietetically acceptable carrier is selected from the group consisting of: diluents, excipients, sticking agents, buffering agents, bulk agents, lubricating agents, and colorants. 8. A method of improving the physiological state of a human comprising administering orally to the human an effective amount of a tablet which can be chewed or dissolved in the mouth consisting essentially of: (a) a vitamin; (b) 10-100 mg of lysine or a pharmaceutically acceptable salt thereof; (c) a sweetener; (d) a pharmaceutically or dietetically acceptable carrier; (e) at least one mineral selected from the group consisting of: manganese (II) gluconate, copper (II) carbonate, zinc oxide, and magnesium oxide; and (f) optionally a flavoring agent capable of masking the flavor of lysine. 9. A method of improving the development and growth of a child or juvenile comprising administering orally to the child or juvenile an effective amount of a tablet which can be chewed or dissolved in the mouth consisting essentially of: (a) a vitamin; (b) 10-100 mg of lysine or a pharmaceutically acceptable salt thereof; (c) a sweetener; (d) a pharmaceutically or dietetically acceptable carrier; (e) at least one mineral selected from the group consisting of: manganese (II) gluconate, copper (II) carbonate, zinc oxide, and magnesium oxide; and (f) optionally a flavoring agent capable of masking the flavor of lysine.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.